GET DAILY SIGNALSSpectral AI (MDAI) Readies Q3 2026 Results as It Shifts Toward Commercialization
Key Takeaways
- Spectral AI (MDAI) is scheduled to report third quarter 2026 results on Tuesday, November 10, 2026, after the Nasdaq market closes, followed by a conference call at 5:00 p.m. Eastern Time.
- Wall Street consensus calls for earnings per share (EPS) of approximately -$0.14 and revenue of roughly $5.33 million, implying year-over-year revenue growth of about 40%.
- The report arrives shortly after the company received U.S. Food and Drug Administration (FDA) De Novo clearance for its DeepView AI System for the burn indication, a milestone that shifts the focus toward commercialization.
- Management has reaffirmed 2026 research and development (R&D) revenue guidance of approximately $18.5 million, which does not include meaningful contributions from DeepView system sales.
- In the same period a year earlier, Spectral AI posted revenue of $3.79 million and an EPS of -$0.13, providing a low base for the expected top-line comparison.
Why This Quarter Stands Out
Spectral AI's third quarter 2026 update carries particular weight because the company is moving from a research-stage developer into a commercial medical-device business. The quarter marks the first full reporting period after the FDA's De Novo clearance of its DeepView AI System for burn care, a regulatory step that opens the door to initial U.S. sales. I am watching closely for signals on commercial launch timing, BARDA funding progress, and expense management. Revenue remains almost entirely tied to government contracts with no product sales recorded yet, so the report serves as an important checkpoint on whether the company can keep losses in check while preparing for its first commercial placements later this year.
What the Numbers Are Expected to Show
Analysts expect Spectral AI to report an EPS of about -$0.14 on revenue near $5.33 million for the third quarter of 2026. That revenue figure would represent growth of roughly 40% from the $3.79 million recorded in the third quarter of 2025, when the company posted a net loss of $3.6 million, or -$0.13 per share. The anticipated increase reflects a partial recovery in BARDA contract activity after prior-year revenue was depressed by the completion of the base phase of the BARDA Project BioShield contract. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
On the guidance front, management has reaffirmed full-year 2026 R&D revenue of approximately $18.5 million, excluding any significant contribution from DeepView system sales. Key metrics to watch include gross margin, which dipped to 31.6% in the second quarter amid a cost-sharing phase with BARDA, along with cash levels, operating expenses, and any fresh commentary on the pace of initial U.S. and U.K. commercial placements.
Market Reaction and Investor Focus
Sentiment heading into the third quarter report centers on the company's recent regulatory breakthrough rather than near-term profitability. Following the FDA De Novo clearance of the DeepView AI System, attention has shifted to execution—specifically, how quickly Spectral AI can convert its BARDA-supported installations into recurring revenue and expand internationally. The stock remains speculative and thinly capitalized, which can amplify volatility around earnings. Risks include the pace of commercial rollouts, margin pressure tied to the BARDA cost-sharing arrangement, and any updates on cash runway. Because the company has beaten consensus EPS estimates in only three of its last seven quarters, investors may react more to forward guidance and commercialization commentary than to the headline figures themselves.
Looking Ahead at Key Catalysts
Looking ahead, the most important item to watch is the timeline for the first commercial sales of the DeepView AI System. Management has indicated that initial placements in the U.S. and U.K. could occur before the end of 2026, with a more material revenue ramp expected in 2027 and 2028. Progress on BARDA-funded installations—potentially supporting up to 30 initial systems and additional units over time—will be a direct signal of near-term traction.
Investors should also monitor gross margin trends as the company operates under its BARDA cost-sharing structure. The second quarter's 31.6% gross margin, down from 45.2% a year earlier, reflects this transition and could remain pressured until higher-margin recurring software and service revenue scales up.
Additional catalysts include expanded UKCA clearance, which the company anticipates in the fourth quarter of 2026, and the planned initiation of a Triage and Treatment Outcome Study designed to demonstrate the clinical benefits of the DeepView system. Finally, balance-sheet strength remains in focus, with roughly $14 million in cash at the end of the second quarter and management indicating it has sufficient working capital for at least a year, though future capital needs could shift if circumstances change.
Using Tickeron AI Tools in My Research
When I want to dig deeper into names like Spectral AI (MDAI), I often turn to Tickeron’s AI Screener to quickly filter for similar medical-device stocks and compare technical patterns and fundamentals. The platform helps surface relevant trade ideas and performance metrics that complement traditional analysis. It has become a regular part of how I stay organized when tracking smaller, catalyst-driven companies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MDAI in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 05, 2026
MDAI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 20 of 24 cases where MDAI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MDAI's RSI Oscillator exited the oversold zone, 16 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 63 cases where MDAI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MDAI as a result. In 72 of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for MDAI just turned positive on November 09, 2026. Looking at past instances where MDAI's MACD turned positive, the stock continued to rise in 34 of 50 cases over the following month. The odds of a continued upward trend are 68%.
Following a +10.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDAI advanced for three days, in 136 of 185 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
MDAI moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MDAI crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDAI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for MDAI entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.978) is normal, around the industry mean (4.142). P/E Ratio (-4.656) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.078) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. MDAI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement